OXFORD - British Biotech plc is planning to use its financial muscle to beef up its product pipeline. The company, which once was pursuing the fully integrated biopharmaceutical company model, now plans to pursue a busy in-licensing program to complement the serial partnering model for its in-house efforts.

British Biotech (LSE:BBG; BBIOY, Oxford, U.K.), with 97.8 million ($156.5 million) in cash at April 30, wants to increase the number of products in development as well as broadening the scope of its portfolio.